Simultaneous Determination of Prostaglandin E1 and Prostaglandin E1 Ethyl Ester in Hairless Mouse Skin Homogenate by High-Performance Liquid Chromatography

  • Published : 2005.10.20


A rapid and specific high-performance liquid chromatographic method was developed and validated for the simultaneous determination of prostaglandin $E_{1}\;(PGE_{1})$ and prostaglandin $E_{1}$ ethyl ester $(PGE_{1}-EE)$ in hairless mouse skin homogenate. The sample treatment procedure involved deproteination and precipitation by acetonitrile. $PGE_{1}$ and $PGE_{1}-EE$ in supernatant were separated in a reversed-phase C18 column without being interfered by other components present in hairless mouse skin homogenate. 9-Anthracenecarboxylic acid was used as an internal standard. The retention times of $PGE_{1}$, 9-anthracenecarboxylic acid and $PGE_{1}-EE$ were, 4.5, 9.5 and 18.0 min, respectively. The assay showed linearity from 1 to $40\;{\mu}g/ml$ for both $PGE_{1}$ and $PGE_{1}-EE$. Precision expressed as RSD ranged from 2.3 to 14.1 % for $PGE_{1}$ and 1.6 to 11.0% for $PGE_{1}-EE$. Accuracy ranged from 100.5 to 119.6 % for $PGE_{1}$ and from 98.0 to 103.7% for $PGE_{1}-EE$. This method was employed successfully to follow the time course of concentrations of $PGE_{1}$ and $PGE_{1}-EE$ in hairless mouse skin homogenate for stability study.


  1. NIH Concensus Conference, Development Panel on Impotence, JAMA, 270, 83-90 (1993)
  2. R.E. Nellans and L.R. Ellis, Pharmacological erection; diagnosis and treatment applications in 69 patients, J. Urol., 138, 52-54 (1987)
  3. P. Halter, Trends in urology, Med Device Diagn. Industry, 12, 52-54 (1990)
  4. J.R. White and R.K. Campbell, Drug induced male sexual dysfunction., U.S. Pharmacist Diabetes Supplement. Complications, November, 44-47(1990)
  5. Y. Mizushima, Lipid microspheres (Lipid emulsions) as a drug carries-overview, Adv. Drug Del. Rev., 20, 113-115 (1996)
  6. R. Igarashi, T. Tdenenaga, T. Matsuda, Distribution of lipid microsphere preparations, Adv. Drug Del. Rev., 20, 147-154 (1996)
  7. H. Porst, The rationale for prostaglandin $E_1$ in erectile failure: a survey of worldwide experience, J. Urol., 155, 802-815 (1996)
  8. O.I. Linet and F.G. Orrinc, Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction, N. Engl. J. Med., 334, 873-877 (1996)
  9. J.D. Engel and K.T. McVary, Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy, Urology, 51, 687-692 (1988)
  10. E.D. Kim and K.T. McVary, Topical prostaglandin $E_1$ for the treatment of erectile dysfunction, J. Urol.15, 3, 1828-1830 (1995)
  11. M. Maggi, S. Filippe and F. Ledda, Erectile dysfunction: from biochemical pharmacology to advances in medical therapy, Eur. J. Endocrinol., 143, 143-154 (2000)
  12. H. Wendel and F.J. Braun, Transdermal prostaglandin composition, U.S. Patent, 5, 380, 760 (1995)
  13. M.T. Sheu, L.-H. Lin, B.W. Spur, P.Y.-K. Wong and H.-S. Chiang, Investigation of the percutaneous penetration of prostaglandin $E_1$ and its ethyl ester, J. Control. Rel., 55, 153-160 (1998)
  14. United States Pharmacopeia 23, Section 1225,'Validation of Compendial Methods,' United States Pharmacopeia Convention, Inc., Rockville, MD, 1995
  15. F. BressolIe, M. Bromet-Petit and M. Audran, Validation of liquid chromatographic and gas chromatographic methods. Applications to pharmacokinetics, J. Chromatogr. B, 686, 3-10 (1996)
  16. G.W. Peng and W.L. Chiou, Analysis of drugs and other toxic substances in biological samples for pharmacokinet studies, J. Chromatogr. B, 531, 3-50 (1990)
  17. A. Parra, J. Garcia-Villanova, V. Rodenas and MD. Gomez, First and second derivative spectrophotometric determination of cefoperazone and sulbactam in injections, J. Pharm. Biomed. Anal., 12, 653-657 (1994)
  18. H. Mahgoub and F.A. Aly, UV-spectrophotometric determination of ampicillin sodium and sulbactam sodium in two-component mixtures, J. Pharm. Biomed. Anal., 17, 1723-1728 (1998)
  19. H. Rosing, Y.W. Man, E. Doyle, A. Buh and J.H. Beijnen, Bioanalytical liquid chromatographic method validation: a review of current practices and procedures, J. Liq. Chromatogr. Related Technol., 23, 329-354 (2000)
  20. International Conference on Harmonization, Note for Guidance on Validation of Analytical Procedures: Methodology, Committee for Proprietary Medical Products, CPMP/ICH/281/ 95 Approval 18 December, 1996
  21. S. Braggio, R.J. Barnaby, P. Grossi and M. Cugola, A strategy for validation of bioanalytical methods, J. Pharm. Biomed. Anal. 14, 375-388 (1996)
  22. S. Ahmed, T. Imai and M. Otagiri, Stereoselective hydrolysis and penetration of propranolol prodrugs: in vitro evaluation using hairless mouse skin, J. Pharm. Sci., 84, 877-883 (1995)
  23. C. Hartmann, J. Smeyers-Verbeke, D.L. Massart and R.D. McDowall, Validation of bioanalytical chromatographic methods, J. Pharm. Biomed. Anal., 17, 193-218 (1998)
  24. Ph. Hubert, P. Chiap, J. Crommen, B. Boulanger, E. Chapuzet, N. Mercier and S. Bervoas-Martin, P. Chevalier, D. Grandjean, P. Lagorce, M. Lallier, M.C. Laparra, M. Laurentie and J.C. Nivet, The SFSTP guide on the validation of chromatographic methods for drug bioanalysis: from the Washington conference to the laboratory, Analytica Chimica Acta, 391, 135-148 (1999)
  25. R.H. Guy, Current status and future prospects of transdermal drug delivery, Pharm. Res., 13, 1765-1768 (1996)
  26. K.B. Sloan, Prodrugs for dermal delivery, Adv. Drug Del. Rev., 3, 67-101 (1989)
  27. J. Rautio, H. Taipale and J. Gynther, In vitro evaluation of acyloxyalkyI ester as dermal prodrugs of detoprofen and naproxen, J. Pharm. Sci., 87, 1662-1628 (1998)
  28. G.B. Kasting, R.L. Smith, B.D. Andersom, K.B. Sloan and M.C. Dekker, Prodrugs for dermal Delivery; Solubility, Molecular Size, and Functional Group Effects. In Prodrugs, Topical and Ocular Drug Delivery, New York, 117-161(1992)